Le Wen Chiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Le Wen Chiu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aileen Y. Chang
Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco
1 shared publication Aimee C. Smidt
Department of Dermatology University of New Mexico (UNM) Albuquerque New Mexico USA
1 shared publicationAndrew Matsumoto
Both authors are affiliated with the Department of Dermatology, University of New Mexico, Albuquerque, NM
1 shared publicationBasema I. Dibas
Department of Pediatrics, Division of Nephrology and Rheumatology UNM Albuquerque New Mexico USA
1 shared publication- Erin Huiras Amerson
Department of Dermatology, University of California, San Francisco, California
1 shared publication - James Gossage
Department of Medicine, Augusta University, Augusta, GA
1 shared publication
Latest Publications
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (3) , e250929
Telangiectatic Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia
Telangiectatic pulmonary arteriovenous malformations, marked by ground-glass opacities with feeding arteries and draining veins, were common in patients with hereditary hemorrhagic telangiectasia and represent true right-to-left shunts.
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 318 (3) , e250929
Telangiectatic Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia
Telangiectatic pulmonary arteriovenous malformations, marked by ground-glass opacities with feeding arteries and draining veins, were common in patients with hereditary hemorrhagic telangiectasia and represent true right-to-left shunts.
- 26 June 2025
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (10) , 1003-1005
Reconstruction of a Large Defect of the Right Midface
- 26 June 2025
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 52 (10) , 1003-1005
Reconstruction of a Large Defect of the Right Midface
- 1 October 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 114 (4) , E24-E25
Community Outreach Benefits Dermatology Residents and Their Patients
Community outreach is an important aspect of residency training. Skin cancer screenings, free clinics, and teledermatology are a few ways in which dermatology residents may take leadership roles and get involved in their local communities. These opportunities not only provide invaluable education for residents, they also deliver specialty care to communities that may otherwise encounter considerable difficulty accessing dermatologic care.
- 1 October 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 114 (4) , E24-E25
Community Outreach Benefits Dermatology Residents and Their Patients
Community outreach is an important aspect of residency training. Skin cancer screenings, free clinics, and teledermatology are a few ways in which dermatology residents may take leadership roles and get involved in their local communities. These opportunities not only provide invaluable education for residents, they also deliver specialty care to communities that may otherwise encounter considerable difficulty accessing dermatologic care.
- 21 August 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (1) , 129-132
Immunoglobulin A vasculitis with periorbital edema and severe renal involvement: A case report
Immunoglobulin A (IgA) vasculitis, or Henoch‐Schonlein purpura, is the most common systemic vasculitis in children, clinically presenting as palpable purpura in combination with arthritis, gastrointestinal involvement, or kidney injury. Subcutaneous edema is reported in patients with IgA vasculitis, and it commonly affects the lower extremities, especially around joints. Here, we report a case of IgA vasculitis with a rare presentation of edema isolated to the periorbital area in a 7‐year‐old boy, who subsequently developed crescentic glomerulonephritis with nephrotic range proteinuria. Isolated periorbital edema is an uncommon cutaneous feature of IgA vasculitis.
- 21 August 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (1) , 129-132
Immunoglobulin A vasculitis with periorbital edema and severe renal involvement: A case report
Immunoglobulin A (IgA) vasculitis, or Henoch‐Schonlein purpura, is the most common systemic vasculitis in children, clinically presenting as palpable purpura in combination with arthritis, gastrointestinal involvement, or kidney injury. Subcutaneous edema is reported in patients with IgA vasculitis, and it commonly affects the lower extremities, especially around joints. Here, we report a case of IgA vasculitis with a rare presentation of edema isolated to the periorbital area in a 7‐year‐old boy, who subsequently developed crescentic glomerulonephritis with nephrotic range proteinuria. Isolated periorbital edema is an uncommon cutaneous feature of IgA vasculitis.
- 1 June 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 113 (6) , E17-E19
Teaching Tips for Dermatology Residents
D ermatology residents interact with trainees of various levels throughout the workday—from undergraduate or even high school students to postgraduate fellows.
- 1 June 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 113 (6) , E17-E19
Teaching Tips for Dermatology Residents
D ermatology residents interact with trainees of various levels throughout the workday—from undergraduate or even high school students to postgraduate fellows.
- 1 February 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 113 (2) , E12-E13
How to Navigate Challenging Patient Encounters in Dermatology Residency
Dermatologists in training are exposed to many different clinical scenarios—from the quick 15-minute encounter to diagnose a case of atopic dermatitis to hours
- 1 February 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 113 (2) , E12-E13
How to Navigate Challenging Patient Encounters in Dermatology Residency
Dermatologists in training are exposed to many different clinical scenarios—from the quick 15-minute encounter to diagnose a case of atopic dermatitis to hours
- 30 December 2022
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 18 (1) , 94-101
Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab
Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lipid vacuoles rimmed by neutrophils with an outer cuff of epithelioid histiocytes/granulomas, with inconsistent presence of Coryneform bacteria within the vacuoles. There is no consensus on the treatment for either IGM or CNGM, which may be managed surgically with wide local excision or mastectomy or medically with antibiotics, steroids, and steroid-sparing immunosuppressive agents. We present a 30-year-old woman with plaque psoriasis and CNGM whose breast symptoms resolved after treatment with the tumor necrosis factor alpha (TNF-α) inhibitor adalimumab, which has not previously been described as a treatment option for CNGM.
- 30 December 2022
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 18 (1) , 94-101
Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab
Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lipid vacuoles rimmed by neutrophils with an outer cuff of epithelioid histiocytes/granulomas, with inconsistent presence of Coryneform bacteria within the vacuoles. There is no consensus on the treatment for either IGM or CNGM, which may be managed surgically with wide local excision or mastectomy or medically with antibiotics, steroids, and steroid-sparing immunosuppressive agents. We present a 30-year-old woman with plaque psoriasis and CNGM whose breast symptoms resolved after treatment with the tumor necrosis factor alpha (TNF-α) inhibitor adalimumab, which has not previously been described as a treatment option for CNGM.
- Open Access
- 12 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 716-720
Management of common scabies and postscabetic itch in adults: Lessons learned from a single-center retrospective cohort study
Common scabies can be difficult to diagnose and treat. There are limited data on the clinical characteristics of patients who may benefit from combined topical permethrin plus oral ivermectin. Postscabetic itch is common, but there is scant data describing its prognosis and management. This study describes the clinical characteristics and evaluates treatment outcomes of participants with common scabies treated with combined topical permethrin plus oral ivermectin and describes the prognosis and management of postscabetic itch. We conducted a single-center retrospective cohort study of participants with common scabies treated with combined topical permethrin plus oral ivermectin therapy and topical permethrin only. Participants previously treated with permethrin and/or ivermectin were excluded. The primary outcome was clinical outcome at follow-up, categorized as cure, worsening, or no change. Secondary outcomes included time from treatment initiation to cure, duration of follow-up after cure, recurrence rate, frequency of postscabetic itch, and duration of postscabetic itch. Of 55 participants treated with combined topical permethrin plus oral ivermectin, 49 (89%) achieved cure, 5 (9%) had no change, and 1 (2%) had worsening disease. Of 48 participants treated with topical permethrin only, 46 (96%) achieved cure, 2 (4%) had no change, and 0 (0%) had worsening disease. Thirty-five participants (34%) experienced postscabetic itch for 52.5 days (interquartile range, 28–135). More participants in the older (mean: 55 years; standard deviation: 21 years; p = .002) combined treatment group experienced postscabetic itch than in the younger (mean: 42 years; standard deviation: 19 years) permethrin-only treatment group (42% vs. 25%; p = .072). These findings support the use of combined topical permethrin plus oral ivermectin therapy in treating common scabies, highlight that postscabetic itch can persist for longer than previously reported, and reveal a potential relationship between older age and postscabetic itch.
- 12 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 716-720
Open AccessManagement of common scabies and postscabetic itch in adults: Lessons learned from a single-center retrospective cohort study
Common scabies can be difficult to diagnose and treat. There are limited data on the clinical characteristics of patients who may benefit from combined topical permethrin plus oral ivermectin. Postscabetic itch is common, but there is scant data describing its prognosis and management. This study describes the clinical characteristics and evaluates treatment outcomes of participants with common scabies treated with combined topical permethrin plus oral ivermectin and describes the prognosis and management of postscabetic itch. We conducted a single-center retrospective cohort study of participants with common scabies treated with combined topical permethrin plus oral ivermectin therapy and topical permethrin only. Participants previously treated with permethrin and/or ivermectin were excluded. The primary outcome was clinical outcome at follow-up, categorized as cure, worsening, or no change. Secondary outcomes included time from treatment initiation to cure, duration of follow-up after cure, recurrence rate, frequency of postscabetic itch, and duration of postscabetic itch. Of 55 participants treated with combined topical permethrin plus oral ivermectin, 49 (89%) achieved cure, 5 (9%) had no change, and 1 (2%) had worsening disease. Of 48 participants treated with topical permethrin only, 46 (96%) achieved cure, 2 (4%) had no change, and 0 (0%) had worsening disease. Thirty-five participants (34%) experienced postscabetic itch for 52.5 days (interquartile range, 28–135). More participants in the older (mean: 55 years; standard deviation: 21 years; p = .002) combined treatment group experienced postscabetic itch than in the younger (mean: 42 years; standard deviation: 19 years) permethrin-only treatment group (42% vs. 25%; p = .072). These findings support the use of combined topical permethrin plus oral ivermectin therapy in treating common scabies, highlight that postscabetic itch can persist for longer than previously reported, and reveal a potential relationship between older age and postscabetic itch.